The Swiss pharmaceutical giant Roche is nothing if not determined in its quest to acquire Illumina, the San Diego-based leader in genetic-sequencing equipment. In January, after Illumina’s board rebuffed Roche’s initial overtures, Roche made a $5.7 billion tender offer directly to shareholders. When that didn’t succeed, it extended the offer to midnight last Friday. Now Roche has upped its offer to $6.5 billion and is urging shareholders to vote for Roche’s independent director nominees at Illumina’s annual meeting to be held on April 18.
Five Questions Companies Should Ask Before Making an Innovation-Driven Acquisition
The Swiss pharmaceutical giant Roche is nothing if not determined in its quest to acquire Illumina, the San Diego-based leader in genetic-sequencing equipment. In January, after Illumina’s board rebuffed Roche’s initial overtures, Roche made a $5.7 billion tender offer directly to shareholders. When that didn’t succeed, it extended the offer to midnight last Friday. Now […]
March 28, 2012
New!
HBR Learning
Innovation and Creativity Course
Accelerate your career with Harvard ManageMentor®. HBR Learning’s online leadership training helps you hone your skills with courses like Innovation and Creativity. Earn badges to share on LinkedIn and your resume. Access more than 40 courses trusted by Fortune 500 companies.
Unlock your team's curiosity and willingness to take smart risks.
Learn More & See All Courses
New!
HBR Learning
Innovation and Creativity Course
Accelerate your career with Harvard ManageMentor®. HBR Learning’s online leadership training helps you hone your skills with courses like Innovation and Creativity. Earn badges to share on LinkedIn and your resume. Access more than 40 courses trusted by Fortune 500 companies.
Unlock your team's curiosity and willingness to take smart risks.